# Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

> **NCT03068624** · PHASE1 · UNKNOWN · sponsor: **M.D. Anderson Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Liver
- Metastatic Uveal Melanoma

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Autologous CD8+ SLC45A2-specific T Lymphocytes
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT03068624
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03068624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03068624, "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03068624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*